YuanMing Capital

YuanMing Capital

YuanMing Capital was founded in 2015 as a private equity firm dedicated exclusively to the global healthcare sector. It operates from dual headquarters in New York and Beijing, reflecting a structural commitment to sourcing and scaling biomedical innovation across the US and China. The firm focuses on venture opportunities, targeting early-stage and growth-stage companies in therapeutics, medical devices, and high-end healthcare services. The firm's investment approach mixes direct venture mandates with a fund-of-funds allocation, providing exposure to both company-level risk and diversified GP portfolios. YuanMing targets seed through late-stage venture rounds, with a particular emphasis on cross-border assets that can leverage Chinese manufacturing scale or US clinical-trial infrastructure. Investment cases include Changfeng Pharmaceutical, which YuanMing backed prior to its successful listing on the Hong Kong Stock Exchange in October 2025 (per the firm, October 2025), and Meisheng Group, a high-end medical device company that completed a strategic financing round exceeding CNY 1.5 billion in September 2025 (per the firm, September 2025). The firm maintains offices in New York and Beijing and communicates primarily through its Chinese-language website, signaling an operational center of gravity in cross-border execution rather than purely domestic US activity. YuanMing's professional headcount has not been publicly disclosed. In January 2026, the firm was ranked among the top performers in the Rongzhong 2025 China Equity Investment List (per the firm, January 2026). No separate philanthropic foundations or operating-business arms have been publicly identified. YuanMing's structural differentiator lies in its explicit dual-city architecture: it is neither a Chinese firm with a US outpost nor a US firm exploring China. This design gives it an unusual mandate to underwrite clinical and regulatory risk in two distinct ecosystems simultaneously, an approach that requires fluency in both FDA and NMPA pathways — a genuine governance and operational separation few healthcare funds replicate without relying on third-party advisors.